李光

摘   要：目的  探討替吉奥联合阿帕替尼治疗晚期胰腺癌的临床疗效。方法  选取2016年5月～2018年5月我院收治的100例晚期胰腺癌患者作为研究对象，按照数字随机分为对照组和研究组，每组50例。对照组采用阿帕替尼治疗，研究组采用替吉奥联合阿帕替尼治疗，比较两组PR、PD及化疗后血常规、肝功、不良反应情况。结果  研究组PR、SD分别为46.00%、28.00%，多于对照组的26.00%、6.00%，差异有统计学意义（P<0.05）;研究组PD占26.00%，少于对照组的68.00%，差异有统计学意义（P<0.05）。研究组白细胞减少、中性粒细胞减少、血小板减少、贫血、乏力、厌食、氨基转移酶升高、腹泻均低于对照组，差异有统计学意义（P<0.05）;研究组5个月、10个月、15个月的无进展生存率，均高于对照组，差异有统计学意义（P<0.05）。结论  替吉奥联合阿帕替尼治疗晚期胰腺癌有利于改善患者的临床症状，降低不良反应发生率，延长患者生命。

关键词：替吉奥;阿帕替尼;晚期胰腺癌;预后

中图分类号： R735.9                                 文献标识码： A                               DOI：10.3969/j.issn.1006-1959.2018.16.025

文章编号：1006-1959（2018）16-0087-03

Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer

LI Guang

（Department of Oncology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China）

Abstract：Objective  To investigate the clinical efficacy of tiggio combined with apatinib in the treatment of advanced pancreatic cancer.Methods  A total of 100 patients with advanced pancreatic cancer admitted to our hospital from May 2016 to May 2018 were randomly divided into the control group and the study group，50 patients in each group.The control group was treated with apatinib，the study group was treated with tiggio combined with apatinib，and the PR，PD，blood routine，liver function and adverse reactions were compared between the two groups.Results  The PR and SD of the study group were 46.00% and 28.00%，respectively，which were more than 26.00% and 6.00% of the control group，the difference was statistically significant（P<0.05）.The PD of the study group accounted for 26.00%，which was less than 68.00% of the control group，the difference was statistically significant（P<0.05）.The study group leukopenia，neutropenia，thrombocytopenia，anemia，fatigue，anorexia，elevated aminotransferase，diarrhea were lower than the control group， the difference was statistically significant（P<0.05）;the study group 5 months，the progression-free survival rate at 10 months and 15 months was higher than that in the control group，and the difference was statistically significant（P<0.05）.Conclusion  Tiggio combined with apatinib in the treatment of advanced pancreatic cancer is beneficial to improve the clinical symptoms，reduce the incidence of adverse reactions and prolong the life of patients.

Key words：Tiggio;Apatinib;Advanced pancreatic cancer;Prognosis

胰腺癌（pancreatic cancer）是临床中较为常见的消化道恶性肿瘤，主要由于环境、生活习惯、遗传等因素引起[1，2]。由于其发病较为隐蔽，早期临床症状不典型，导致确诊时80%左右的患者已為晚期，致使治疗的最佳时期被错过，大多患者需以化疗的方式进行治疗，少于20%的患者可进行手术[3]。目前临床常采用阿帕替尼对晚期胰腺癌患者进行治疗，但单使用一种药物的疗效存在局限性。本文旨在探讨替吉奥联合阿帕替尼治疗晚期胰腺癌的临床疗效，现报告如下。

1资料与方法

1.1一般资料  选取2016年5月～2018年5月黑龙江省佳木斯市中心医院收治的100例晚期胰腺癌患者作为研究对象，本次研究已经医院伦理委员会批准。纳入标准：①所有患者均经影像学或病理诊断确诊为胰腺癌;②患者均具备正常的精神状态，试验过程中可以积极配合;③患者及家属均知情，均自愿参加，同时签署知情同意书。排除标准：①合并心、肾、肝等重大器官疾病;②合并其他肿瘤;③处于妊娠或哺乳期。……